USE OF CABERGOLINE IN THE TREATMENT OF EYE DISEASES CAUSED BY ELEVATED VASCULAR ENDOTHELIAL GROWTH FACTOR LEVELS

摘要

A method is provided for using of type-2 dopaminergic receptor agonists, for example, cabergoline, in treatment of eye diseases caused by an elevated level of vascular endothelial growth factor (VEGF), particularly in treatment or prevention of diseases of an eye retina resulting from an increase in permeability of blood vessels and their angiogenesis using cabergoline, a dopaminergic D2 receptor agonist.